An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...
Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.
2d
GlobalData on MSNSanofi’s Sarclisa combo approved in Japan for newly diagnosed MMSanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...
Sanofi India, Schaeffler India share prices will remain in focus on Thursday as will declare dividend today. The meeting of ...
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
4d
GlobalData on MSNSanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
9d
GlobalData on MSNSanofi moves closer to selling controlling stake in $17bn-valued OpellaSanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.
Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results